Apolipoprotein C-III (APOC3) Antibody
299€ (50 µl)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Apolipoprotein C-III (APOC3) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx402497
tested applications
ELISA, IHC
Description
Apolipoprotein C-III (APOC3) Antibody is a Recombinant Rabbit Monoclonal antibody for the detection of Human APOC3.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Primary Antibodies |
| Immunogen Target | Apolipoprotein C-III (APOC3) |
| Host | Rabbit |
| Reactivity | Human |
| Recommended Dilution | IHC: 1/50 - 1/200. Optimal dilutions/concentrations should be determined by the end user. |
| Clonality | Monoclonal |
| Conjugation | Unconjugated |
| Isotype | IgG |
| Expression | Recombinant |
| Purification | Purified by affinity chromatography. |
| Size 1 | 50 µl |
| Size 2 | 100 µl |
| Form | Liquid |
| Tested Applications | ELISA, IHC |
| Buffer | PBS, pH 7.4, 150 mM NaCl, 0.02% sodium azide and 50% glycerol. |
| Availability | Shipped within 5-10 working days. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| UniProt ID | P02656 |
| Alias | APOC3, APOCIII, HALP2, apolipoprotein C3, Apo-C3, ApoC-3,apo-CIII, and apolipoprotein C-III |
| Background | Antibody anti-APOC3 |
| Status | RUO |
Descripción
APOC3 is a critical regulator of triglyceride-rich lipoprotein (TRL) metabolism, primarily associated with VLDL, HDL, and chylomicrons. APOC3 inhibits lipoprotein lipase (LPL) and hepatic uptake of remnant lipoproteins by interfering with the binding of TRLs to heparan sulfate proteoglycans (HSPG) and the low-density lipoprotein receptor (LDLR). Elevated APOC3 levels are strongly associated with hypertriglyceridemia, atherogenic dyslipidemia, and increased risk of cardiovascular disease. APOC3 expression is regulated by dietary factors, insulin, and nuclear receptors such as PPAR-alpha. Loss-of-function mutations in the APOC3 gene result in lower plasma triglycerides and reduced cardiovascular risk, highlighting its potential as a therapeutic target for lipid disorders. APOC3 also modulates inflammatory responses and has been implicated in non-alcoholic fatty liver disease (NAFLD), where elevated levels contribute to hepatic lipid accumulation. Pharmacological inhibitors of APOC3, such as antisense oligonucleotides, are being developed to lower plasma triglycerides and improve lipid profiles in hyperlipidemic patients.
Related Products
Human APOC3 (Apolipoprotein C-III) ELISA Kit
Ver Producto
Recombinant Human APOC3
Ver Producto